Apolipoprotein E4 Mediates the Association between Midlife Dyslipidemia and Cerebral Amyloid in Aging Women

C Szoeke; AM Goodwill; A Gorelik; L Dennerstein; K Caeyenberghs; S Simpson; E Hill; S Campbell

Journal article

Apolipoprotein E4 Mediates the Association between Midlife Dyslipidemia and Cerebral Amyloid in Aging Women

C Szoeke, AM Goodwill, A Gorelik, L Dennerstein, K Caeyenberghs, S Simpson, E Hill, S Campbell

Journal of Alzheimer S Disease | IOS PRESS | Published : 2019

DOI: 10.3233/JAD-180815

Abstract

Cerebral amyloid-β (Aβ) plaques are the hallmark biomarker of Alzheimer's disease (AD) and are detectable decades before clinical symptoms. Modifying risk factors associated with Aβ accrual offers an opportunity for AD prevention. While midlife vascular health is linked to AD; there is minimal longitudinal evidence regarding the effect of midlife lipids on Aβ. We examined the association between midlife lipids and Aβ 20 years later. One hundred and twenty-two women had serum lipid profiles in midlife (1992, 45-57 years), and cerebral imaging, genotyping, and cognition measured 20 years later (2012/13, 66-77 years). Imaging was performed in 2012/13 via F-18 Florbetaben positron emission tomog..

View full abstract

University of Melbourne Researchers

Cassandra Szoeke Author

Alex Gorelik Author

Lorraine Dennerstein Author

Steve Simpson-Yap Author

Related Projects (3)

WOMEN'S HEALTHY AGEING COGNITIVE PROJECT

The changes of Alzheimer’s disease occur a decade prior to symptoms. Therefore we need longitudinal prospective data over 20 years to determ..

THE ASSOCIATIONS BETWEEN COGNITIVE DECLINE AND GENETIC POLYMORPHISMS, HORMONES AND CARDIOVQSCULAR RISK FACTORS IN WOMEN

Dementia, a major cause of morbidity and mortality in ageing women, has been linked to hormonal changes and genes. If factors associated wit..

MODIFIABLE RISK FACTORS FOR COGNITIVE IMPAIRMENT IN AGEING

This study focuses on age-related decline in cognitive function in midlife.Early detection of people at risk will allow the introduction of ..

Grants

Awarded by VicHealth

Funding Acknowledgements

Funding for the Healthy Ageing Program (HAP) has been provided by the National Health and Medical Research Council (NHMRC Grants 547600, 1032350 & 1062133), Ramaciotti Foundation, Australian Healthy Ageing Organisation, the Brain Foundation, the Alzheimer's Association (NIA320312), Australian Menopausal Society, Bayer Healthcare, Shepherd Foundation, Scobie and Claire Mackinnon Foundation, Collier Trust Fund, J.O. & J.R. Wicking Trust, Mason Foundation and Alzheimer's Australia. Inaugural funding was provided by VicHealth and the NHMRC. The Principal Investigator of HAP (CSz) is supported by the National Health and Medical Research Council. EH is supported by an Australian Government Research Training Program Scholarship.